Technology
Health
Biotechnology

Voyager Therapeutics

$25.33
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.00 (4.13%) As of 12:27 PM EDT today
+$1.00 (4.13%) Today

Why Robinhood?

You can buy or sell VYGR and other stocks, options, ETFs, and crypto commission-free!

About VYGR

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. Read More The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Employees
123
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
889.53M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
386.93K
High Today
$25.60
Low Today
$24.41
Open Price
$24.62
Volume
157.54K
52 Week High
$28.79
52 Week Low
$7.76

Collections

Technology
Health
Biotechnology
Therapy
Medical
2015 IPO
US
North America

VYGR Earnings

-$0.81
-$0.35
$0.12
$0.58
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 6, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.